Pancreatic Cancer Research

ResearcherColumbia UniversityActive in the last 2 years

Christoph Benedikt Westphalen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5310-3754; OpenAlex author ID A5053960245. Sources: OpenAlex.

Their work

Papers
39 (first author 3, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
112
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: 2 papers · 2017: 5 papers · 2018: 4 papers · 2019: 1 paper · 2020: 5 papers · 2021: 4 papers · 2022: 2 papers · 2023: 6 papers · 2024: 6 papers · 2025: 1 paper · 2026: 1 paper

Papers 39

  1. Precision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond. Last author DOI 10.1007/s11523-026-01236-x↗
  2. Sustained Clinical Response to Olaparib in a Patient with Metastatic Pancreatic Cancer and Somatic ATM Mutation R2034Ter: A Case Report. Co-author DOI 10.1159/000545975↗
  3. Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO … Last author DOI 10.1007/s00432-024-05954-5↗
  4. Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection? Co-author DOI 10.1007/s12094-023-03323-1↗
  5. Stereotactic body radiotherapy for pancreatic cancer - A systematic review of prospective data. Co-author DOI 10.1016/j.ctro.2024.100738↗
  6. Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical trial. First author DOI 10.1016/j.ejca.2024.113926↗
  7. Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades … Co-author DOI 10.1016/j.esmoop.2024.102944↗
  8. The neoadjuvant approach in resectable pancreatic ductal adenocarcinoma: lessons learned. First author DOI 10.1016/s2468-1253(23)00451-x↗
  9. Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison … Co-author DOI 10.1007/s00432-022-04112-z↗
  10. In-vitro model to mimic T cell subset change in human PDAC organoid co-culture. Co-author DOI 10.1007/s00432-023-05100-7↗
  11. Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. Last author DOI 10.1007/s11523-023-00950-0↗
  12. Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort. Co-author DOI 10.1016/j.ejca.2023.04.012↗
  13. Clinical Impact of Structured Post-Operative Surveillance in Resected Pancreatic Adenocarcinoma: Results from a Retrospective Cohort Study. Co-author DOI 10.1159/000528722↗
  14. Case of a Patient With Pancreatic Cancer With Sporadic Microsatellite Instability Associated With a BRAF Fusion Achieving Excellent Response to Immunotherapy. Last author DOI 10.1200/po.22.00650↗
  15. [Treatment of metastatic pancreatic cancer]. Last author DOI 10.1007/s00108-022-01334-8↗
  16. Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 stu… Co-author DOI 10.1016/j.esmoop.2022.100388↗
  17. Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel. Co-author DOI 10.1007/s12094-021-02620-x↗
  18. Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of… Co-author DOI 10.1016/j.ejca.2020.12.029↗
  19. Interleukin-1β-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression. Co-author DOI 10.1136/gutjnl-2019-319912↗
  20. Chart review of diagnostic methods, baseline characteristics and symptoms for European patients with pancreatic cancer. Co-author DOI 10.2217/fon-2020-0749↗
  21. Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled… Co-author DOI 10.1007/s00432-019-03061-4↗
  22. Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer - translational results from the AIO-PK0104 Phase 3 st… Co-author DOI 10.1038/s41416-020-01029-7↗
  23. [Erlotinib plus Gemcitabine in metastatic pancreatic cancer: Results from a non-interventional trial]. Co-author DOI 10.1055/a-1071-8177↗
  24. First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observa… Co-author DOI 10.1136/esmoopen-2019-000587↗
  25. Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib - results from a non-interventional mul… Co-author DOI 10.1186/s12885-020-6636-7↗
  26. Repurposed Drugs in Pancreatic Ductal Adenocarcinoma: An Update. First author DOI 10.1097/ppo.0000000000000372↗
  27. POLE gene hotspot mutations in advanced pancreatic cancer. Co-author DOI 10.1007/s00432-018-2746-x↗
  28. β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2017.11.007↗
  29. Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospect… Co-author DOI 10.1016/j.ejca.2018.02.008↗
  30. Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer. Co-author DOI 10.1093/annonc/mdy417↗
  31. Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer - A retrospective cohort study. Co-author DOI 10.1016/j.thromres.2017.06.021↗
  32. Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer. Co-author DOI 10.1038/bjc.2017.115↗
  33. Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. Co-author DOI 10.1080/2162402x.2017.1310358↗
  34. Mismatch-repair-deficient metastatic pancreatic ductal adenocarcinoma with a germline PALB2 mutation: unusual genetics, unusual clinical course. Co-author DOI 10.1093/annonc/mdw564↗
  35. Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs). Co-author DOI 10.3390/medsci5020014↗
  36. Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2016.03.016↗
  37. Safety of palliative chemotherapy in advanced pancreatic cancer. Co-author DOI 10.1080/14740338.2016.1177510↗
  38. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ccr.2014.04.021↗
  39. Genetically engineered mouse models of pancreatic cancer. Co-author DOI 10.1097/ppo.0b013e31827ab4c4↗

Closest collaborators

The 25 strongest of 112 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Volker Heinemann · 25 shared papers, 2016–2025 · strength 2.88
  2. Stefan Hubert Boeck · 21 shared papers, 2016–2024 · strength 2.30
  3. Michael Haas · 20 shared papers, 2016–2024 · strength 2.04
  4. Steffen Ormanns · 15 shared papers, 2016–2023 · strength 1.44
  5. Stephan Krüger · 15 shared papers, 2016–2023 · strength 1.32
  6. Klara Dorman · 7 shared papers, 2023–2024 · strength 1.10
  7. Jens Werner · 10 shared papers, 2016–2023 · strength 1.04
  8. Kathrin Heinrich · 6 shared papers, 2023–2025 · strength 0.97
  9. Lena Weiss · 6 shared papers, 2023–2024 · strength 0.95
  10. Julia V. Mayerle · 6 shared papers, 2020–2025 · strength 0.86
  11. Georg Beyer · 5 shared papers, 2023–2025 · strength 0.85
  12. Dirk Waldschmidt · 6 shared papers, 2020–2024 · strength 0.83
  13. Danmei Zhang · 5 shared papers, 2023–2024 · strength 0.78
  14. Grainne Mary O'Kane · 2 shared papers, 2024–2026 · strength 0.66
  15. Maximilian Reichert · 4 shared papers, 2018–2026 · strength 0.65
  16. Anke Reinacher‐Schick · 5 shared papers, 2018–2024 · strength 0.64
  17. Bernhard Willibald Renz · 6 shared papers, 2017–2023 · strength 0.64
  18. Kenneth P. Olive · 5 shared papers, 2012–2026 · strength 0.56
  19. Jens Thomas Siveke · 5 shared papers, 2017–2024 · strength 0.56
  20. Matthias Ilmer · 5 shared papers, 2017–2023 · strength 0.49
  21. Monica Niger · 2 shared papers, 2023–2026 · strength 0.44
  22. Michael Ståhl · 3 shared papers, 2021–2024 · strength 0.43
  23. Jan Goesta D’Haese · 4 shared papers, 2017–2023 · strength 0.41
  24. Marlies Vornhülz · 2 shared papers, 2024–2025 · strength 0.41
  25. Paul Rogowski · 2 shared papers, 2024–2025 · strength 0.41

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.